Literature DB >> 3551695

Effect of oral treatment with pantethine on platelet and plasma phospholipids in IIa hyperlipoproteinemia.

D Prisco, P G Rogasi, M Matucci, R Paniccia, R Abbate, G F Gensini, G G Neri Serneri.   

Abstract

In a single-blind, crossover, completely randomized study, the effects of oral treatment with pantethine or placebo on fatty acid composition of plasma and platelet phospholipids were investigated in 10 IIa hyperlipoproteinemic patients. A significant decrease of total cholesterol and total phospholipids was observed both in plasma and in platelets after a twenty-eight-day treatment. In plasma, pantethine induced a decrease of the ratio sphingomyelin/phosphatidylcholine. Moreover, a relative increase of n3-polyunsaturated fatty acids both in plasma and in platelet phospholipids and a decrease of arachidonic acid in plasma phospholipids were observed. These results indicate that pantethine can affect plasma and platelet lipid composition with possibly favorable influences on the determinants of cell membrane fluidity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3551695     DOI: 10.1177/000331978703800307

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  3 in total

1.  Pantethine rescues a Drosophila model for pantothenate kinase-associated neurodegeneration.

Authors:  Anil Rana; Erwin Seinen; Katarzyna Siudeja; Remco Muntendam; Balaji Srinivasan; Johannes J van der Want; Susan Hayflick; Dirk-Jan Reijngoud; Oliver Kayser; Ody C M Sibon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

2.  Elevated cell-specific microparticles are a biological marker for cerebral dysfunctions in human severe malaria.

Authors:  Joël Bertrand Pankoui Mfonkeu; Inocent Gouado; Honoré Fotso Kuaté; Odile Zambou; Paul Henri Amvam Zollo; Georges Emile Raymond Grau; Valéry Combes
Journal:  PLoS One       Date:  2010-10-14       Impact factor: 3.240

3.  Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded placebo and diet-controlled investigation.

Authors:  Malkanthi Evans; John A Rumberger; Isao Azumano; Joseph J Napolitano; Danielle Citrolo; Toshikazu Kamiya
Journal:  Vasc Health Risk Manag       Date:  2014-02-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.